Evidence map›Paper›PMID 33163411›Full record

ArticleFrontiers in oncology2020

Impact of T Cell Repertoire Diversity on Mortality Following Cord Blood Transplantation.

F Milano, R O Emerson, R Salit, K A Guthrie, L A Thur, A Dahlberg, H S Robins, C Delaney

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

F MilanoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
R O EmersonAdaptive Biotechnologies, Seattle, WA, United States.
R SalitClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
K A GuthrieClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
L A ThurClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
A DahlbergClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
H S RobinsClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
C DelaneyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Fred Hutch Cancer Center · USAdaptive Biotechnologies (United States) · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCord blood transplantation (CBT) recipients are at increased risk of mortality due to delayed immune recovery (IR). Prior studies in CBT patients have shown that recovery of absolute lymphocyte count is predictive of survival after transplant. However, there are no data on the association of T-cell receptor (TCR) and clinical outcomes after CBT. Here we retrospectively performed TCR beta chain sequencing on peripheral blood (PB) samples of 34 CBT patients.

methodsAll patients received a total body irradiation based conditioning regimen and cyclosporine and MMF were used for graft

resultsMedian age was 27 (range 1-58 years) and most of the patients (n = 27) had acute leukemias. There were 15 deaths occurring between 34 to 335 days after transplant. Seven deaths were due to relapse. Rapid turnover of T cell clones was observed at each time point, with TCR repertoires stabilizing by 1-year posttransplant. TCR diversity values at day 100 for patients who died between 100 and 365 days posttransplant were significantly lower than those of the surviving patients (p = 0.01).

conclusionsUsing a fast high-throughput TCR sequencing assay we have demonstrated that high TCR diversity is associated with better patient outcomes following CBT. Importantly, this assay is easily performed on posttransplant PB samples, even as early as day 28 posttransplant, making it an excellent candidate for early identification of patients at high risk of death.

Indexed as

cord blood transplantationdelayed immune recoveryimmune reconstitutionT-cell receptor sequencingT-cell repertoire diversity

Identifiers

PMID33163411
PMCPMC7582952
OpenAlexW3091785755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.